BRAF and neoplasm: BRAF-mutated tumours had a lower net survival [BRAF wildtype 5-year net survival 66.5% (95% CI 62.1–60.1) vs. BRAF-mutated 5-year net survival 55.9% (95% CI 52.7–59.2)], particularly in stage II disease [BRAF wildtype 5-year net survival 66.8% (95% CI 63.7–70.2) vs. BRAF-mutated 5-year net survival 55.5% (95% CI 50.5–61.1)] [Figure 1; Table S10 (see Supporting Information)].